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Alzheimer’s disease is the most common cause of dementia and its prevalence is expected to increase in the coming
years. Therefore, accurate diagnosis is crucial for patients, clinicians and researchers. Neuroimaging techniques have
provided invaluable information about Alzheimer’s disease and, owing to recent advances, these methods will have
an increasingly important role in research and clinical practice. The purpose of this article is to review recent
neuroimaging studies of Alzheimer’s disease that provide relevant information to clinical practice, including a new
modality: in vivo amyloid imaging. Magnetic resonance imaging, single photon emission computed tomography
and
18F-fluorodeoxyglucose-positron emission tomography are currently available for clinical use. Patients with
suspected Alzheimer’s disease are commonly investigated with magnetic resonance imaging because it provides
detailed images of brain structure and allows the identification of supportive features for the diagnosis.
Neurofunctional techniques such as single photon emission computed tomography and
18F-fluorodeoxyglucose-
positron emission tomography can also be used to complement the diagnostic investigation in cases of uncertainty.
Amyloid imaging is a non-invasive technique that uses positron emission tomography technology to investigate the
accumulation of the b-amyloid peptide in the brain, which is a hallmark of Alzheimer’s disease. This is a promising
test but currently its use is restricted to very few specialized research centers in the world. Technological innovations
will probably increase its availability and reliability, which are the necessary steps to achieve robust clinical
applicability. Thus, in the future it is likely that amyloid imaging techniques will be used in the clinical evaluation of
patients with Alzheimer’s disease.
KEYWORDS: Alzheimer’s disease; Neuroimaging; Amyloid imaging; Diagnosis; Classification.
Ferreira LK, Busatto GF. Neuroimaging in Alzheimer’s disease: current role in clinical practice and potential future applications. Clinics.
2011;66(S1):19-24.
Received for publication on March 15, 2011; Accepted for publicaiton on March 16, 2011
E-mail: kobuti@yahoo.com / gbusatto@terra.com.br
Tel.: 55 11 3069 7651
INTRODUCTION
Alzheimer’s disease (AD) is the most common cause of
dementia in the general population. Clinical diagnosis of
AD is based on a history of progressive and characteristic
cognitive decline and the presence of objective cognitive
deficits. Exclusion of other diagnoses such as depression,
hypothyroidism, other dementias and non-AD brain lesions
is an integral part of the diagnostic evaluation.
1 Since AD is
the most common type of dementia and its burden is
expected to grow substantially owing to aging of the
population, improving the diagnostic accuracy of AD is
critical.
Neuroimaging examinations are an essential part of the
diagnostic investigation of dementia. These examinations
are important not only to identify non-AD pathological
processes that can lead to cognitive decline (e.g. brain
tumors or cerebrovascular disease) but also to search for
biological markers that provide supportive features for the
diagnosis of AD. These include medial temporal lobe
atrophy as assessed with magnetic resonance imaging
(MRI) and reduced glucose metabolism in temporoparietal
regions on functional neuroimaging with
18F-fluorodeox-
yglucose-positron emission tomography (FDG-PET).
2
Though there is no test to diagnose AD accurately in vivo,
in the past few years advances in neuroimaging technology
have changed our understanding of AD. This review will
focus on recent neuroimaging studies of AD that provide
relevant information to clinical practice. We will also
examine a new neuroimaging modality – amyloid imaging
– and discuss whether such technique can be combined with
innovative methods of data processing and analysis to
improve AD diagnostic accuracy.
NEUROIMAGING AND AD: UNDERSTANDING THE
BRAIN CHANGES UNDERLYING THE SYMPTOMS OF
THE DISEASE
Over the past decades, many research investigations have
applied neuroimaging techniques to gather information
about the anatomical and functional brain changes related
to AD. Table 1 summarizes the clinical utility of neuroima-
ging modalities used in patients with suspected AD.
Thanks to major improvements in image acquisition,
processing and analysis, these studies have conducted
detailed assessments of the human brain in vivo comparing
groups of patients with dementia and unaffected elderly
volunteers. A very brief summary of clinically relevant
neuroimaging findings in samples of patients with AD is
presented in Table 2.
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19MRI has become the most used tool for cerebral imaging
in vivo for the assessment of dementia, as it provides
detailed information about brain structure, thus allowing
the characterization of regional brain atrophy and the
identification of causes for the cognitive decline, such as
white matter lesions, cerebral infarcts and brain tumors.
Conversely, computed tomography (CT) investigations are
seldom part of the outpatient diagnostic work-up of
cognitive complaints owing to its lower spatial resolution.
Notwithstanding, CT can be used in cases of contraindica-
tions for MRI (e.g. pacemaker). MRI is used to evaluate the
anatomical features of the brain because it provides a clear
distinction between gray matter, white matter and cere-
brospinal fluid. The most consistent findings in MRI studies
of patients with AD are atrophy in the medial temporal lobe
(hippocampus, amygdala, entorhinal cortex and parahippo-
campal gyrus), ventricular enlargement and smaller total
brain volume.
3,4 MRI data have also been used to compare
AD with other neurodegenerative conditions, such as
dementia with Lewy bodies, frontotemporal lobar degen-
eration and Parkinson’s disease dementia. Despite some
heterogeneity in the results of these studies, they provide
consistent evidence for the presence of a characteristic
pattern of gray matter atrophy in AD involving mainly the
medial temporal lobe, insula and temporoparietal cortices.
3
The dynamics of atrophy in AD has been assessed by
cross-sectional and longitudinal MRI studies. Initially,
atrophy is most pronounced in the medial temporal lobe;
3
next, the temporal neocortex is involved; then, the atrophic
pattern extends to the parietal and frontal lobes.
5,6 These
descriptions are in accordance with the results of previous
neuropathological studies that examined postmortem brains
of patients with different stages of AD.
7
Since the pathological processes that lead to AD are
known to begin years before the clinical syndrome, long-
itudinal studies have provided valuable information about
the preclinical stages of AD, such as mild cognitive
impairment (MCI), a condition characterized by cognitive
decline in the absence of clinical dementia. Recent meta-
analyses have shown that gray matter atrophy is a
consistent finding in elderly subjects with MCI and also
that medial temporal lobe atrophy is a neurostructural
biomarker of MCI conversion to AD.
8,9
Neurofunctional imaging modalities, such as FDG-PET
and regional cerebral blood flow imaging with single
photon emission computed tomography (SPECT) provide,
respectively, information about regional glucose metabo-
lism and brain perfusion. Several research studies have
evaluated samples of patients with AD relative to elderly
controls using neurofunctional modalities such as FDG-PET
and SPECT. The characteristic pattern found in AD is of
hypometabolism/hypoperfusion in the temporoparietal
cortex.
10,11 A recent meta-analysis found that hypometabo-
lism/hypoperfusion of the inferior parietal lobules and
precuneus is the most consistent neurofunctional finding in
AD in comparison with healthy elderly subjects.
9 Moreover,
longitudinal neurofunctional imaging studies have demon-
strated hypometabolism/hypoperfusion in the parietal lobe
of MCI converters in comparison with those who did not
convert to AD.
9 These functional imaging techniques can be
useful in cases of diagnostic uncertainty despite thorough
evaluation
12 and have been shown to be valuable to
distinguish AD from frontotemporal dementia.
13 However,
they should not be used as the only imaging modality
because they do not allow an adequate evaluation of brain
structure.
14
A distinct regional finding resulting from neurostructural
and neurofunctional imaging studies – respectively, medial
temporal lobe atrophy and parietal hypoperfusion/hypo-
metabolism – has been reported by authors who assessed
patients with AD using both MRI and neurofunctional
methods (FDG-PET or SPECT).
15,16 The neurofunctional
decline in the parietal lobe is thought to be due to a
Table 1 - Neuroimaging modalities in patients with suspected Alzheimer’s disease.
Modality Information afforded Clinical utility in dementia Current availability
MRI Visualization of gray
matter, white matter
and cerebrospinal
fluid
Important to identify non-Alzheimer’s
disease etiologies
Useful to characterize supportive
features for the diagnosis of Alzheimer’s
disease (medial temporal lobe atrophy)
Available in developed geographic
regions. Limited availability in
underdeveloped areas
CT Identification of gross
brain abnormalities
Identification of large lesions. Useful if there are
contraindications for magnetic resonance imaging
Widely available
FDG-PET Regional brain glucose
metabolism
Useful in cases of diagnostic uncertainty despite
a thorough evaluation
12
SPECT/FDG-PET should not be used as the only
imaging measure
14
Limited to specialized centers
SPECT Regional brain perfusion
Amyloid imaging
with PET
Identification of amyloid
deposition in the brain
In the future may be used as a very sensitive
(though nonspecific) test for Alzheimer’s disease
Only in a very few specialized
research centers in the world
CT = computed tomography; FDG-PET =
18F-fluorodeoxyglucose-positron emission tomography; MRI = magnetic resonance imaging; SPECT = single
photon emission computed tomography.
Table 2 - Clinically relevant neuroimaging findings in
patients with Alzheimer’s disease.
Imaging Modality Major findings in Alzheimer’s disease
MRI Gray matter atrophy beginning in the
medial temporal lobe and progressing
to the temporal neocortex, parietal
cortex and frontal cortex
FDG-PET and SPECT Hypometabolism/hypoperfusion in
temporoparietal cortex
DTI Loss of white matter integrity in limbic
and cortico-cortical tracts
Amyloid imaging Amyloid deposition in the cortex
DTI = diffusion tensor imaging; FDG-PET =
18F-fluorodeoxyglucose-
positron emission tomography; MRI = magnetic resonance imaging;
SPECT = single photon emission computed tomography.
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20‘diaschisis’ effect, caused by disruption in the white matter
bundles that connect the atrophic temporal lobe structures
to the parietal lobe.
16
White matter volume can also be measured with MRI.
Studies comparing groups of patients with AD against
elderly controls have found volumetric reduction in the
corpus callosum, fornix and the cingulum bundle in AD
samples.
16,17 More subtle white matter abnormalities can be
detected using a novel MRI technique called diffusion
tensor imaging. By measuring water diffusivity, diffusion
tensor imaging studies allow researchers to draw inferences
about the integrity of white matter.
18 In AD, widespread
white matter disruption has been demonstrated, involving
both limbic pathways (e.g. fornix) and cortico-cortical tracts
(e.g. uncinate fasciculus and corpus callosum).
19,20
Although a very important source of knowledge about the
pathophysiology of the disease, the brain imaging mod-
alities cited above have limited diagnostic utility because
their findings are not specific to AD and they are not
sufficiently sensitive to detect mild or preclinical disease
stages. This is important not only to clinical practice but also
to the development of new therapies: researchers seeking
disease-modifying agents are aware that an efficient drug
should ideally be started before patients present with overt
dementia but, in order to choose who will benefit from such
therapy, we need accurate diagnostic tools.
21,22
AMYLOID DEPOSITION AS A BIOLOGICAL MARKER
OF AD
In clinical practice, a definite diagnosis of AD is usually
not possible owing to the requirement for histopathological
examination.
1 Moreover, owing to the heterogeneity of
clinical manifestations and low specificity of the cogni-
tive deficits, the diagnosis of AD can be challenging.
23
Neuropathological studies that analyzed postmortem brain
tissue found that the clinical diagnosis of AD is frequently
inaccurate.
24,25
Accumulation of the b-amyloid peptide in the brain is a
hallmark of AD.
26 b-Amyloid is the product of sequential
proteolytic cleavage of the amyloid precursor protein by
b- and c-secretases.
27 Senile plaques found in the brain of
patients with AD are primarily composed of insoluble
deposits of b-amyloid.
28 Until recently, the investigation of
amyloid deposition in living humans was limited because it
used to rely on brain biopsy or postmortem examinations.
Fortunately, in recent years, the development of radio-
pharmaceutical agents aimed at identifying amyloid deposi-
tion has allowed researchers to study in vivo amyloid
deposition in humans.
29 Briefly, amyloid imaging consists
of an injection of a radiolabeled ligand targeting amyloid
aggregates and use of positron emission tomography (PET)
technology to acquire images of the brain in order to display
foci of abnormal amyloid accumulation.
29
Despite the recent development of this PET technology,
radiolabeled biomarkers for amyloid imaging have already
been used in several research studies. The vast majority of such
investigations have employed Pittsburgh compound B labeled
with carbon-11. These studies have shown that amyloid
deposition: 1) occurs years before clinical dementia,
30,31 2) is
related to cortical atrophy and cognitive decline,
30-32 3) is more
intense in patients with MCI who convert to AD than in
nonconverters
33,34 and 4) plateaus when clinical dementia is
established (while other neurodegenerative processes such as
brain atrophy keep progressing).
31,35 For the next few years, it
is expected that the amount of information provided by
amyloid imaging studies will sharply increase. For instance,
this imaging modality is now used in a sub-study of the
Alzheimer’s Disease Neuroimaging Initiative, a large long-
itudinal (6-year) multicentric project in the USA involving
cohorts of elderly controls and subjects with MCI and AD,
aimed at validating neuroimaging and cerebrospinal fluid/
blood biomarkers for use in clinical trials of AD treatments. In
this project, subjects are investigated with MRI and FDG-PET
and then followed, thus allowing measurements of change in
these biomarkers at different disease stages.
36
Amyloid deposition is not pathognomonic of AD and, in
fact, it is rather unspecific. For instance, it can be found in
dementia with Lewy bodies and in cognitively intact elderly
subjects.
36,37 Therefore, a positive amyloid biomarker scan
may have limited diagnostic value; on the other hand, a
negative result from such a sensitive imaging test can be
informative because amyloid deposition is a defining
feature of AD.
37,38 Thus, the immediate clinical usefulness
of sensitive imaging biomarkers for brain amyloid deposi-
tion would be to rule out the presence of significant levels of
b-amyloid in the brain. In other words, a negative result
would mean that AD is an unlikely diagnosis. As an
example, researchers showed that amyloid biomarkers
could be useful to differentiate between AD and fronto-
temporal dementia.
37,39,40
Amyloid imaging could also be useful as a non-invasive
biomarker allowing a more adequate selection of subjects
without overt dementia but with a high likelihood of
progressing to AD in clinical trials of disease-modifying
agents.
21,41 Perhaps this imaging tool could even become
useful to measure the efficacy of new drugs,
42 as suggested
by the results of a recent study that used amyloid imaging to
quantify the reduction of b-amyloid load in patients treated
with anti-amyloid antibody.
43
One logistic concern is the short physical half-life of
carbon-11, which prevents the applicability of Pittsburgh
compound B-PET imaging to wider populations in clinical
settings. This has raised interest in the development of
amyloid imaging agents that can be labeled with fluorine-18
(
18F), which has a longer decay half-life. Florbetapir
(Amyvid
TM) is one of the most promising of such agents,
not only owing to the longer radioactive half-life of
18F, but
also because of the rapid kinetics and stable plateau of
uptake of florbetapir in the brain following intravenous
administration.
44 These properties increase its potential
availability and allow short post-dose waiting periods and
flexibility in timing of image acquisition.
44 Recent investiga-
tions have shown that
18F-florbetapir PET imaging per-
formed during life in a sample of elderly patients from
hospice, long-term care and community healthcare facilities
accurately predicted the presence of b-amyloid in the brain
as verified at autopsy of the same subjects.
45
In spite of the above advances, there are still important
difficulties to be overcome before amyloid imaging with
PET can be seen as a useful resource in clinical practice for
the diagnostic work-up for dementia. Indeed, florbetapir
has been rejected by a recent preliminary document of the
United States Food and Drugs Administration (FDA), which
highlighted the problem of inconsistent reader-to-reader
image interpretation.
46 This represents a set-back that will
force the neuroimaging community to improve the relia-
bility of amyloid imaging interpretations.
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21The FDA document is based on the first phase 3 study
focused on the relationship between florbetapir imaging
and postmortem b-amyloid pathology.
45 Results based on the
binary classification (positive6negative) of the mean rating
given by three trained nuclear medicine physicians resulted
in an impressive 93% sensitivity.
45 However, the detailed
FDA report pointed out that there was too much variation in
the individual reader performance; for instance, one reader
demonstrated an unacceptably low sensitivity of 55%.
Furthermore, ‘‘in over one-third of the subjects, at least
one reader would have had a different binary interpretation
of amyloid status from the other two readers’’.
46 Based on
the reader inconsistency, this document concluded that ‘‘the
data did not produce evidence of clinical usefulness’’.
46
So, what would be the next step?
One of the most relevant messages from the FDA
document is the following: ‘‘The available data suggest that
the variability in
18F-florbetapir PET test results more likely
stems from variability in image interpretation rather than
image acquisition’’.
46 In other words, if this imaging
modality is one day to be widely used in clinical practice,
then efforts should be focused on how to improve the
reliability of imaging interpretation.
One way would be to improve the physicians’ training,
with lengthier and/or more sophisticated learning protocols.
In real world clinical settings, this would not only be
expensive but also limit the availability of this method to a
few physicians and patients. An alternative would be to
develop automated methods of image analysis that could
help physicians make more accurate interpretations.
Numerous results from recent years have provided evidence
that automated techniques have a great potential to advance
the diagnostic accuracy of neuroimaging methods for
dementia and other neurological and psychiatric disorders.
PATTERN CLASSIFICATION APPROACHES IN
NEUROIMAGING STUDIES: FUTURE APPLICATIONS
IN THE DIAGNOSIS OF DEMENTIA
Neuropsychiatric researchers commonly perform between-
group comparisons using neuroimaging data to obtain
valuable insights into the neuropathological processes that
underlie the diseases. The statistical methods of most of the
studies cited in the sections above are based on this principle.
Nevertheless, such an approach cannot be used in clinical
practice because neuroimaging techniques must provide
reliable information of individual scans in order to be
diagnostically useful. For this reason, researchers have
recently developed computer-based, automated classifica-
tion methods that analyze substantial amounts of informa-
tion looking for a pattern that characterizes the disease.
Then, the model can be tested for diagnostic accuracy.
Methods for automated classification of brain imaging data
can provide high accuracy in the evaluation of individual
cases and for this reason, it has been recently suggested that
such techniques could become established as useful
diagnostic tools for clinical applications.
47
For instance, these methods – also known as pattern
classification approaches – have already been applied in
MRI studies to differentiate:
N - patients with AD from controls,with 87–95% accuracy
48-51
N - AD and frontotemporal lobar degeneration with 89%
accuracy
49
N - MCI from healthy controls, with 90% accuracy
52
N - subjects with MCI who convert to AD and nonconver
ters (81% accuracy)
53
N - children with and without autism (81% accuracy)
54
N - patients with schizophrenia from controls (90% accuracy).
55
Pattern classification approaches have also been used in
neurofunctional imaging studies designed to differentiate
between patients with AD and controls,
56 AD and fron-
totemporal dementia,
57 patients with schizophrenia and
healthy subjects,
58 schizophrenia and bipolar disorder
59 and
depression and controls.
60 Moreover, these automated
classifiers can be designed to combine multiple biomarkers
(e.g. demographic data, structural and functional neuroima-
ging, genotyping information and laboratory results, such
as cerebrospinal fluid biomarkers) in order to improve
successful classification.
61
Despite these recent findings, we are not aware of any
study using pattern classification approaches to classify
amyloid imaging data on an individual basis. Given the
insufficient consistency in reader-to-reader interpretation of
individual amyloid imaging data as pointed out by the
recent FDA document discussed above,
46 testing the
accuracy of pattern classification methods in this neuroima-
ging modality seems a sensible next step.
CONCLUSION
Neuroimaging techniques have led to an increasingly
large body of knowledge about AD by allowing the study of
the brain in living subjects. These imaging methods are not
only highly important research tools, but they are also
commonly used in the evaluation of patients presenting
with dementia in order to improve the accuracy of clinical
diagnosis and identify brain lesions contributing to the
cognitive decline. A recent major advance is the develop-
ment of amyloid imaging techniques that allow in vivo
identification of amyloid deposition in the brain. This
imaging modality has already yielded important results
and will likely determine an increase in the diagnostic
accuracy of AD in the near future.
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